CITA Biomedical's Proprietary Program to End Cocaine Dependence Used To Successfully Treat First U.S. Patient for Cocaine Addiction
Patient Had No Withdrawal Symptoms and After Treatment No Cravings for Alcohol or Cocaine
BEVERLY HILLS, Calif., July 16 /PRNewswire-FirstCall/ -- CITA Biomedical, Inc. (OTC Bulletin Board: DTOX) a growing leader in the treatment of substance dependency, today announced that the first U.S. Detoxification and NeuroAdaptation (DNA) for Cocaine patient was successfully treated for cocaine dependence. DNA for Cocaine is a part of a family of treatments called DNA for Addictions. The DNA for Addictions treatment family includes DNA for Alcohol, DNA for Cocaine, DNA for Alcohol and Cocaine, and DNA for Crack Cocaine. CITA has patents pending for the family of DNA treatments.
(Photo: newscom.com )
The patient, a 35-year-old male first used marijuana and alcohol at age 15. At age 17 he was free-basing which eventually turned into a $2000 a week cocaine and crack cocaine habit, including the consumption of a fifth of alcohol or two six-packs of beer daily plus marijuana use. "I've probably tried 20 or more programs including residential, in-patient, out-patient, AA, and NA," said the patient. "There are a lot of advantages to DNA but the biggest advantage is that you don't even think of alcohol or cocaine! You don't crave it. You just don't think about it! I've tried to quit in the past but it never worked out until now." The treatment was administered to the patient for less than an hour daily over three consecutive days. The patient experienced no symptoms of withdrawal.
DNA for Cocaine establishes a new treatment regimen in the fight against cocaine addiction, a disorder that impedes normal neural functioning of the brain and body systems as a whole. Cocaine addiction causes cravings, possible brain damage, and can lead to potentially life-threatening withdrawal symptoms. Historically, the disorder of cocaine addiction has been treated only through behavioral intervention, but the CITA DNA treatment provides a solution for treating both the physiological and psychological components of this devastating condition.
The patients that were treated in Europe last year experienced a less than 25 percent relapse rate, compared to a more than 75 percent relapse rate generally associated other accepted means of treating cocaine addiction. The new treatment was also shown to reduce the time, pain, and costs associated with withdrawal, and allowed the patients to return to a productive level of functioning within hours of the treatment's completion.
"We are pleased to begin another proven safe and effective DNA for addictions treatment in the U.S. We anticipate that this patient will be the first of thousands that we will treat for alcohol and cocaine dependence in the coming year," said Joseph Dunn, president and CEO of CITA Biomedical. "DNA took years to develop and continues to be extremely successful in Europe with our CITA affiliate. CITA is pleased to finally help address the devastation to society caused by cocaine and crack cocaine dependence."
About CITA Biomedical, Inc.
CITA Biomedical, Inc., headquartered in Beverly Hills, Calif., focuses on the innovative treatment of addiction. The company holds the U.S. patent for its successful UROD (Ultra Rapid Opiate Detoxification) treatment method. UROD is the only clinically tested and effective treatment method to rapidly detoxify individuals addicted to opiate-based drugs, including heroin within four to six hours with few, if any, withdrawal symptoms. The company recently announced a new family of revolutionary treatments, Detoxification and NeuroAdaptation (DNA) for Addictions. The first treatments from this family treat cocaine, cocaine, and poly-drug addictions. To date CITA has grown its business through internal expansion and now seeks compatible, leading, and complementing technologies and acquisitions to enhance its corporate portfolio. CITA Biomedical, Inc. has two operating divisions CITA Americas, Inc., and AltTPro, Inc. For more information, please visit www.citabio.com
UROD is a registered trademark of CITA Biomedical, Inc.
For further information please contact: Judy Ryon of CITA Biomedical, Inc., +1-310-550-4971, jryon@citabio.com; or Laurel Moody of Vision Corporate Consulting, +1-212-446-6109, laurel@visioncc.net, for CITA Biomedical, Inc.
MAKE YOUR OPINION COUNT - Click Here tbutton.prnewswire.com
SOURCE CITA Biomedical, Inc.
CONTACT: Judy Ryon of CITA Biomedical, Inc., +1-310-550-4971,
jryon@citabio.com; or Laurel Moody of Vision Corporate Consulting,
+1-212-446-6109, laurel@visioncc.net, for CITA Biomedical, Inc.
Photo: newscom.com
PRN Photo Desk, 888-776-6555 or 212-782-2840
Web site: citabio.com |
